Go or no go? Oncology dominates upcoming decisions
Astrazeneca’s Lynparza is due US approval decisions in prostate and ovarian cancers, while Bristol's Opdivo’s fate will be determined in lung cancer.
AACR 2020 – Verastem reveals the logic behind its Kras deal
A combination of Verastem’s small molecules shows promise in Kras-driven ovarian cancer, but shares fall on toxicity concerns.
AACR 2020 preview – no Tigit, but plenty of novel mechanisms
Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.
Novo Nordisk’s quiet entry into the year of Alzheimer’s
An upcoming study could show whether diabetes drugs like Novo’s Victoza might have an effect on slowing cognitive decline.
The sellside falls out of love with Opdivo
An analysis of the sellside’s consensus forecast changes reveals the winners and losers of 2019.
Clinical win gives Verona a kiss of life
For Verona’s long-suffering shareholders today brought an unexpected clinical success with ensifentrine.
As Nash shifts again, the focus remains on Genfit’s big readout
Genfit investors, who early next year will see the Resolve-It study yield data, digest further developments in the Nash space.
The other shoe drops for Gossamer’s GB001
Novartis’s similarly acting fevipiprant had failed in asthma in October, and today it fails in the more important severe setting.
Breaking down Beigene’s latest deal with the west
A multifaceted tie-up effectively gives Beigene a net $1.5bn fund-raising and several Amgen drugs to sell locally.
